Radioactive bullet targets Hard-to-Treat prostate cancer

NCT ID NCT06970119

Recruiting now Disease control Sponsor: Yunhe Pharmaceutical (Tianjin) Co., Ltd Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new drug called INR102, which delivers radiation directly to prostate cancer cells. It is for men with a specific type of advanced prostate cancer that has spread and no longer responds to hormone therapy. The trial will check safety, how the drug moves through the body, and whether it can shrink tumors or lower PSA levels.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: INR102 injection (a radioactive drug that targets prostate cancer cells)
What this could lead to: If successful, this could offer a new treatment option for men with advanced prostate cancer that has stopped responding to hormone therapy.
What could go wrong: This is an early-phase trial with only 55 participants, so results may not apply to everyone. The drug is radioactive and may cause side effects like damage to healthy tissues.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC CASTRATION-RESISTANT PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

castration-resistant prostate carcinoma metastatic prostate carcinoma prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PROSTATE CANCER

Contacts and locations

Locations

Affiliated Hospital of Jiangnan University
NOT_YET_RECRUITING

Wuxi, Jiangsu, 214000, China
Tianjin Cancer Hospital Airport Hospital
RECRUITING

Tianjin, Tianjin Municipality, 300000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.